Most people who book a hair visit in Roseville are not bald. A part is widening, a ponytail is shrinking, or a hairline has moved back a centimeter a year. That pattern — androgenetic alopecia — is follicles spending less time in growth and more time resting. The follicle is often still there. It is smaller, and the hair it makes is finer.

That is the only opening this kind of care has. If the follicle is gone and replaced by scar, no injection brings it back. If it is dormant or miniaturized, the question is whether a signal can push it back into a growth cycle. The pairing clinics advertise is autologous Platelet-Rich Fibrin (PRF) and next-generation cellular Exosomes. They are not the same thing, they do not have the same evidence, and neither replaces a workup.

At Lifespark Health & Wellness we see this from Roseville, Rocklin, Lincoln, and the rest of Placer County. Ramneek Kahlon, FNP-C starts with the cause. Iron, thyroid, postpartum shed, traction, medication, and hormones all mimic “I need a treatment.” Injecting a scalp that is low on ferritin wastes a good biologic.

PRF is your own blood, clotted into a matrix

Platelet-rich fibrin comes from a small blood draw. Unlike classic PRP, injectable PRF is spun without an anticoagulant. Platelets and white cells sit in a fibrin web. The theory — still a theory for hair — is that the web releases growth factors more slowly than liquid PRP: PDGF, VEGF, TGF-beta, IGF-1, and EGF.

In the chair, your name is on the tube. The scalp is numbed, PRF is placed in the thinning zone, and you leave the same day. Mild swelling and pinpoint marks for a day or two are normal.

PRF vs PRP, without the marketing

• PRP has the larger evidence base. A 2025 review of 43 randomized trials (1,877 people) found activated PRP increased hair density versus placebo. Pooled gains in earlier analyses sit around 25 to 36 extra hairs per square centimeter. Real. Modest. Not a new head of hair.
• PRF is the second-generation story: no additive, fibrin scaffold, slower release. For pattern hair loss the published set is small. A 2024 review found three pattern-hair studies, 22 patients, no control group, with about 73 percent showing some visible improvement. There is still no randomized trial showing PRF beats PRP on the scalp.
• “PRF is better than PRP” is a mechanism claim, not a trial result. Patients who want the option with more trials get PRP. Patients who want an autologous fibrin matrix are the PRF conversation.

Exosomes are the message, not the cell

An exosome is a vesicle cells release to talk to other cells. It carries proteins and RNA. It is not a stem cell, and it does not become a follicle. The pitch is that vesicles from cultured mesenchymal cells can tell a miniaturizing follicle to stay in growth longer.

Human data is early. A 2025 review pooled eleven studies, samples from 1 to 85 people, follow-up from six weeks to twelve months. Reported density gains ran from about 9.5 to 35 hairs per square centimeter. Designs were too different to pool. A signal, not a standard of care.

There are no FDA-approved exosome products for hair loss, or for any other condition. Products marketed as exosomes and intended to treat a disease are unapproved drugs and unlicensed biologics unless they are in an authorized study. The agency has warned companies selling exosome products with hair-growth claims. A clinic that promises FDA-cleared exosome hair reversal is describing a product that does not exist.

If exosomes are discussed here, they are discussed as investigational adjunctive care, with source and limits named before a vial is opened. They are not a cure, and they are not a substitute for minoxidil, anti-androgen therapy, or a transplant consult when those are the right tools.

Why the two get combined

PRF brings your platelets and a fibrin scaffold. Exosomes, if used, bring an outside signal. One is autologous. One is a lab product with a regulatory cloud. Stacking them does not add their best-case studies together. It is a protocol for a patient who has had the workup, understands the evidence gap, and still wants a non-surgical attempt at the thinning zone.

A serious series is: diagnose, correct what is correctable, photograph, treat the mapped zone, repeat over months, re-photograph. Density that is real shows up on the photos, not in the mirror after one Saturday.

Who should not start here

• Scarring alopecias until dermatology has quieted the disease.
• A slick scalp whose only reservoir is the donor zone. That is a transplant conversation.
• An active postpartum shed before the cause and the timeline are clear.
• Pregnancy, scalp infection, or a casual add-on with no photos and no labs.

What the Roseville visit decides

The consult is the product. History, scalp exam, same-light photos, labs when the story is not classic pattern loss, then a written plan: PRF series or not, whether an exosome adjunct is even on the table, what topical or oral therapy still belongs, and what success means in hairs rather than adjectives. The quote comes after the map. Lifespark is at 130 Diamond Creek Place, Suite 100, Roseville.

Questions from Roseville and Rocklin

Does this reverse thinning? It can thicken miniaturized hair and slow a widening part in people who still have follicles and who finish a series. It does not reverse a bald scalp, and it does not work in everyone.

Is it natural? PRF is your blood. Exosomes used in clinics come from donor cell cultures. Only half of “natural hair loss treatment” is natural.

How many sessions? Three to four in the first four to six months is convention, not a trial endpoint. Photos decide whether the next session is earned.

When? Shedding can tick up in month one. New growth, if it comes, is a three-to-six-month read.

How is this different from a transplant? Non-surgical means we are signaling follicles you still have. Surgery moves follicles from the back to a place they are gone.

‍

Book Online Consultation or call (916) 270-6002. Bring a supplement list and a photo from two years ago.

Education only. Not a diagnosis, not a guarantee of regrowth, not an offer of an FDA-approved exosome drug.

‍